| Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study M Zander, S Madsbad, JL Madsen, JJ Holst The Lancet 359 (9309), 824-830, 2002 | 1788 | 2002 |
| Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients MB Toft-Nielsen, MB Damholt, S Madsbad, LM Hilsted, TE Hughes, ... The Journal of Clinical Endocrinology & Metabolism 86 (8), 3717-3723, 2001 | 1240 | 2001 |
| Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients T Vilsbøll, T Krarup, CF Deacon, S Madsbad, JJ Holst Diabetes 50 (3), 609-613, 2001 | 1212 | 2001 |
| Angiotensin-receptor blockade versus converting–enzyme inhibition in type 2 diabetes and nephropathy AH Barnett, SC Bain, P Bouter, B Karlberg, S Madsbad, J Jervell, ... New England Journal of Medicine 351 (19), 1952-1961, 2004 | 1041 | 2004 |
| 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial CW Le Roux, A Astrup, K Fujioka, F Greenway, DCW Lau, L Van Gaal, ... The Lancet 389 (10077), 1399-1409, 2017 | 794 | 2017 |
| The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects LL Kjems, JJ Holst, A Vølund, S Madsbad Diabetes 52 (2), 380-386, 2003 | 748 | 2003 |
| Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, AG Juul, JJ Holst The Journal of Clinical Endocrinology & Metabolism 88 (6), 2706-2713, 2003 | 673 | 2003 |
| Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients T Vilsbøll, T Krarup, S Madsbad, J Holst Diabetologia 45, 1111-1119, 2002 | 673 | 2002 |
| Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of … T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup, O Schmitz, JP Courrèges, ... Diabetes care 30 (6), 1608-1610, 2007 | 634 | 2007 |
| Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects T Vilsbøll, T Krarup, S Madsbad, JJ Holst Regulatory peptides 114 (2-3), 115-121, 2003 | 515 | 2003 |
| Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? FK Knop, T Vilsbøll, PV Højberg, S Larsen, S Madsbad, A Vølund, JJ Holst, ... Diabetes 56 (8), 1951-1959, 2007 | 506 | 2007 |
| Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with … PV Højberg, T Vilsbøll, R Rabøl, FK Knop, M Bache, T Krarup, JJ Holst, ... Diabetologia 52, 199-207, 2009 | 464 | 2009 |
| Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. C Orskov, J Jeppesen, S Madsbad, JJ Holst The Journal of clinical investigation 87 (2), 415-423, 1991 | 457 | 1991 |
| Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. MB Toft-Nielsen, S Madsbad, JJ Holst Diabetes care 22 (7), 1137-1143, 1999 | 438 | 1999 |
| Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide … S Madsbad, O Schmitz, J Ranstam, G Jakobsen, DR Matthews, ... Diabetes care 27 (6), 1335-1342, 2004 | 426 | 2004 |
| Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study J Jeppesen, TW Hansen, S Rasmussen, H Ibsen, C Torp-Pedersen, ... Journal of the American College of Cardiology 49 (21), 2112-2119, 2007 | 404 | 2007 |
| Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects SH Jacobsen, SC Olesen, C Dirksen, NB Jørgensen, KN Bojsen-Møller, ... Obesity surgery 22, 1084-1096, 2012 | 385 | 2012 |
| Low birthweight is associated with specific changes in muscle insulin-signalling protein expression SE Ozanne, CB Jensen, KJ Tingey, H Storgaard, S Madsbad, AA Vaag Diabetologia 48, 547-552, 2005 | 374 | 2005 |
| Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance NB Jørgensen, SH Jacobsen, C Dirksen, KN Bojsen-Møller, L Naver, ... American Journal of Physiology-Endocrinology and Metabolism 303 (1), E122-E131, 2012 | 359 | 2012 |
| Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes JJ Holst, FK Knop, T Vilsbøll, T Krarup, S Madsbad Diabetes care 34 (Suppl 2), S251, 2011 | 337 | 2011 |
